Cerus (NASDAQ:CERS) Share Price Crosses Above 200-Day Moving Average – What’s Next?

Cerus Corporation (NASDAQ:CERS) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.48 and traded as high as $2.21. Cerus shares last traded at $2.16, with a volume of 1,812,820 shares trading hands.

Analyst Upgrades and Downgrades

CERS has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cerus in a research note on Wednesday, October 8th. Wall Street Zen upgraded Cerus from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Cerus has an average rating of “Hold” and an average target price of $4.00.

Cerus Stock Up 7.5%

The firm has a market cap of $414.91 million, a PE ratio of -27.00 and a beta of 1.55. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.29 and a current ratio of 1.89. The company’s 50-day simple moving average is $1.68 and its two-hundred day simple moving average is $1.48.

Cerus (NASDAQ:CERS) last issued its quarterly earnings data on Thursday, November 6th. The biotechnology company reported $0.00 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.02. The firm had revenue of $60.24 million during the quarter, compared to the consensus estimate of $55.12 million. Cerus had a negative net margin of 8.01% and a negative return on equity of 27.58%. On average, analysts predict that Cerus Corporation will post -0.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cerus

A number of large investors have recently made changes to their positions in the business. Focus Partners Advisor Solutions LLC increased its stake in shares of Cerus by 65.2% during the second quarter. Focus Partners Advisor Solutions LLC now owns 19,930 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 7,866 shares during the period. CIBC Bancorp USA Inc. bought a new stake in Cerus in the third quarter valued at $31,000. Dynamic Technology Lab Private Ltd purchased a new position in Cerus during the 1st quarter valued at $32,000. Aquatic Capital Management LLC purchased a new position in Cerus during the 3rd quarter valued at $35,000. Finally, HUB Investment Partners LLC bought a new position in Cerus in the 2nd quarter worth $42,000. 78.37% of the stock is currently owned by institutional investors.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.